AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06575322
Drug: Carboplatin（ neoadjuvant）
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Trial: NCT06575322
Drug: Paclitaxel （neoadjuvant）
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Trial: NCT05669950
Drug: Lu AG13909
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT00000971
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000971
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05636904
Drug: prostaglandin F2a analogue in vehicle solution high dose
RxNorm normalized name: Prostaglandin F2a tromethamine
DrugBank: Dinoprost tromethamine (DB01160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment for 24 weeks
Trial: NCT05636904
Drug: prostaglandin F2a analogue in vehicle solution low dose
RxNorm normalized name: Prostaglandin F2a tromethamine
DrugBank: Dinoprost tromethamine (DB01160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment for 24 weeks
Trial: NCT05636904
Drug: Minoxidil 5% Topical Solution
RxNorm normalized name: Minoxidil 5% Topical solution
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical treatment for 24 weeks
Trial: NCT02136511
Drug: Idelalisib
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib 150 mg tablet administered orally twice daily
Trial: NCT02136511
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab administered intravenously starting at 375 mg/m\^2 at Week 0 and continuing with a dose of 500 mg/m\^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.
Trial: NCT04709913
Drug: HU6
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
Trial: NCT06550336
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 20 mg (4 tablets) twice a week, specifically on days 1, 4, 8, 11, 15, 18, 22, and 25.Each 4-week period constitutes one treatment cycle.
Trial: NCT04656288
Drug: BI 764198 - Formula A
RxNorm normalized name: Combretastatin A-1 bis(phosphate)
DrugBank: OXI-4503 (DB05143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 764198
Trial: NCT04656288
Drug: BI 764198 - Formula C
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 764198
Trial: NCT04656288
Drug: BI 764198 - Formula D
RxNorm normalized name: calcium bis[(2ξ)-D-glycero-D-gulo-heptonate]
DrugBank: Calcium glucoheptonate (DB00326)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BI 764198
Trial: NCT05522192
Drug: Mitoxantrone liposome
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I: 24mg/m2, 30 mg/m2, 36mg/m2, IV, d1; Phase II: RP2D.
Trial: NCT05522192
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I/II: 100mg po d1，200mg po d2，400mg po d3-28.
Trial: NCT05383131
Drug: HEC585
RxNorm normalized name: Hec585
DrugBank: Yinfenidone (DB18330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mulltiple doses of HEC585 for up to 10 days
Trial: NCT05383131
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mulltiple doses of Pirfenidone for up to 3 days
Trial: NCT05383131
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mulltiple doses of Nintedanib for up to 7 days
Trial: NCT05095116
Drug: APT-1011 3 mg HS
RxNorm normalized name: tetracycline
DrugBank: APT-101 (DB18003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
Trial: NCT06414941
Drug: Dexmedetomidine administration
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: atients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
Trial: NCT06414941
Drug: Dexmedetomidine plus low-dose esketamine administration
RxNorm normalized name: ethinyl estradiol
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
Trial: NCT06414941
Drug: Dexmedetomidine plus high-dose esketamine administration
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
Trial: NCT04814472
Drug: BLD-0409
RxNorm normalized name: BLD-0409
DrugBank: Cudetaxestat (DB18203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to active product.
Trial: NCT00051090
Drug: Telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally at a daily dosage of 600 mg for a period of 48 weeks
Trial: NCT00051090
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally at a total daily dosage of 300 mg for Weeks 24-48
Trial: NCT00051090
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally at a daily dose of 600 mg
Trial: NCT00051090
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight
Trial: NCT00051090
Drug: Abacavir
RxNorm normalized name: Abacavir
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally twice daily in doses of 300 mg
Trial: NCT00439504
Drug: Lobeline
RxNorm normalized name: lobeline
DrugBank: Lobeline (DB05137)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06238011
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine(Precedex Pfizer) prepared in concentration 0.1 mcg/kg/ml total volume50 ml by nurse anesthetist at preprocedure room, start dexmedetomidine by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass (loading 1mcg/kg in 10 minutes then 0.5 mcg/kg/hour). Record patients data by nurse anesthetist
Trial: NCT04135677
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Rivaroxaban 20mg Duration of treatment: 12 weeks(12 weeks for DAPT afterwards)
Trial: NCT04135677
Drug: DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Aspirin 100mg and clopidogrel 75mg Duration of treatment:24 weeks
Trial: NCT04629495
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RAPA will be administered orally 1mg daily
Trial: NCT04776629
Drug: Orticumab
RxNorm normalized name: Orticumab
DrugBank: Orticumab (DB16653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope
Trial: NCT04487613
Drug: Moringa oleifera leaf
RxNorm normalized name: MORINGA OLEIFERA LEAF
DrugBank: Moringa oleifera leaf (DB14362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg capsule
Trial: NCT04982575
Drug: Semaglutide 2.4 mg
RxNorm normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Trial: NCT04982575
Drug: Cagrilintide 2.4 mg
DrugBank: Cagrilintide (DB18887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Trial: NCT05089383
Drug: Utrogestan
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PROSPECTIVE STUDY
Trial: NCT05430243
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once daily empagliflozin 10mg+/- diuretics
Trial: NCT05202314
Drug: Immunotherapy (Camrelizumab)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After clinical success of colonic stenting, regardless of the MSI state, patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 2-3 weeks after the last cycle chemotherapy
Trial: NCT04427540
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin 10 micrograms IM
Trial: NCT01606358
Drug: Carboplatin and / or taxol chemotherapy
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
Trial: NCT05068180
Drug: low-dose neuroleptanalgesia
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.
Trial: NCT05339373
Drug: Aceclofenac film-coated tablet 100 mg
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aceclofenac is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 100 mg of aceclofenac.
Trial: NCT05715944
Drug: AZD 1222
RxNorm normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Azdone]
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine
Trial: NCT06229067
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab at a dose of 1200 mg via intravenous infusion every three weeks. Adebrelimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Trial: NCT06229067
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronomic oral vinorelbine 20 mg every other day. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Trial: NCT00038272
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00038272
Drug: Amdoxovir
RxNorm normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04313088
Drug: Eluxadoline 100 mg
RxNorm normalized name: eluxadoline 100 MG
DrugBank: Eluxadoline (DB09272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eluxadoline 100mg by mouth twice daily with food
Trial: NCT04760977
Drug: Drugs administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antifibrinolytics, analgesics, sedatives, neuromuscular blocking agents
Trial: NCT04948814
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg/kg/day
Trial: NCT05183841
Drug: Bronchodilator (Ipratropium and Fenoterol)
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 puffs of Ipratropium (20mcg) and Fenoterol (50mcg) via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
Trial: NCT00213109
Drug: Miglitol
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05191290
Drug: unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard heparin at 2500 IU i.v. bolus and then 2000 IU/h continuously i.v. for anticoagulation during plasmapheresis
Trial: NCT05191290
Drug: Sodium Citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8% sodium citrate at approx. 27 mmol/h i.v. for anticoagulation during plasmapheresis
Trial: NCT04924192
Drug: Anlotinib Hydrochloride capsules
RxNorm normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A multi-target receptor tyrosine kinase inhibitor
Trial: NCT04924192
Drug: Irinotecan Hydrochloride for Injection
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An inhibitor of DNA topoisomerase Ⅰ
Trial: NCT05514015
Drug: rituximab combined with corticosteroids
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction therapy:~Rituximab intravenous infusion of 1g, d1, d15, combined with glucocorticoid therapy, oral prednisolone, initial dose of 0.5mg/(kg·d), once a day, after 8 weeks of treatment, reduce by 5mg every 4 weeks until 0.25mg/kg, this dose was maintained for 8 weeks, and then reduced by 2.5mg every 4 weeks, until 5-10mg is maintained, and the total course of treatment was about one year or so;
Trial: NCT05514015
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Control group (treated with Rituximab monotherapy treatment) :Rituximab intravenous infusion of 1g, d1, d15
Trial: NCT05831878
Drug: Disitamab vedotin
RxNorm normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0mg/kg, iv, day1, every 2 weeks
Trial: NCT05256108
Drug: Oxycodone 40 mg
RxNorm normalized name: oxyCODONE 40 mg oral tablet, extended release
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be administered a single dose of 6 capsules containing oxycodone and placebo in a randomized crossover manner
Trial: NCT05256108
Drug: Tramadol 600 mg
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be administered a single dose of 6 capsules containing tramadol in a randomized crossover manner
Trial: NCT05256108
Drug: Cebranopadol 600 µg
RxNorm normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
Trial: NCT05523102
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol/acetaminophen
Trial: NCT06261489
Drug: THC
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomly assigned to the study treatment. THC dose will be gradually increased until 25 mg. Treatment will be taken orally at bedtime for 15 weeks.
Trial: NCT06261489
Drug: CBD
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be randomly assigned to the study treatment. CBD dose will be gradually increased until 50 mg. Treatment will be taken orally at bedtime for 15 weeks.
Trial: NCT05256108
Drug: Cebranopadol 1000 µg
RxNorm normalized name: menthol
DrugBank: Cebranopadol (DB12830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
Trial: NCT05790681
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneously fixed dose of insulin icodec (700 U/mL) that is 5.6 U/kg bodyweight.
Trial: NCT04676477
Drug: HER3-DXd
RxNorm normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
DrugBank: Zenocutuzumab (DB15559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion at a starting dose of 3.2 mg/kg Q3W
Trial: NCT04676477
Drug: HER3-DXd
RxNorm normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
DrugBank: Zenocutuzumab (DB15559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
Trial: NCT04676477
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration at 40 mg or 80 mg once daily
Trial: NCT04676477
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
Trial: NCT04676477
Drug: HER3-DXd
RxNorm normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
DrugBank: Zenocutuzumab (DB15559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion 5.6 mg/kg Q3W
Trial: NCT04676477
Drug: HER3-DXd
RxNorm normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
DrugBank: Zenocutuzumab (DB15559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion 4.8 mg/kg Q3W
Trial: NCT04676477
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration at 80 mg once daily
Trial: NCT06530550
Drug: PI3K inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linperlisib 80mg QD orally, or Duvelisib 25mg BID orally, with a 28-day cycle. Efficacy will be evaluated once per cycle during the first year, and once every two cycles thereafter. Treatment will continue for up to 24 cycles, or until disease progression, lack of response within the first 6 cycles, or the occurrence of intolerable toxicity, whichever occurs first
Trial: NCT05969041
Drug: MT-302 (A)
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-302 is an investigational drug
Trial: NCT05531123
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200 mg I.V. Q3W on the day 1
Trial: NCT05531123
Drug: gemcitabine and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cisplatin 70mg/m2 I.V. Q3W on the day 1, dose fractionation is allowed ;Gemcitabine 1000mg/m2 I.V. Q3W on the day 1 and day 8
Trial: NCT05631717
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 (1×10\^6IU) will be injected subcutaneously every other day for 2 weeks (7 times), with an interval of 2 weeks. 4 weeks is a cycle, and three cycles were continuously treated for 12 weeks.
Trial: NCT05673980
Drug: Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in the vitamin D2 group received 200,000 IU of vitamin D2 orally on the first day of the trial and again two weeks later
Trial: NCT05264038
Drug: OC514 (Low dose)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose level of OC514
Trial: NCT05264038
Drug: OC514 (High dose)
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose level of OC514